Immunosuppression in hepatitis C virus-infected patients after kidney transplantation.

Détails

ID Serval
serval:BIB_B335B0B01784
Type
Article: article d'un périodique ou d'un magazine.
Sous-type
Synthèse (review): revue aussi complète que possible des connaissances sur un sujet, rédigée à partir de l'analyse exhaustive des travaux publiés.
Collection
Publications
Titre
Immunosuppression in hepatitis C virus-infected patients after kidney transplantation.
Périodique
Contributions to Nephrology
Auteur(s)
Manuel O., Baid-Agrawal S., Moradpour D., Pascual M.
ISSN
1662-2782 (Electronic)
ISSN-L
0302-5144
Statut éditorial
Publié
Date de publication
2012
Volume
176
Pages
97-107
Langue
anglais
Notes
Publication types: Journal Article ; Review
Résumé
Hepatitis C virus (HCV) infection is an important health problem in kidney transplant recipients with a significantly higher prevalence than in the general population. Kidney transplantation remains the treatment of choice for most HCV-infected patients with end-stage kidney disease, in spite of lower patient and graft survival as compared to HCV-negative patients. Immunosuppression likely has significant consequences on HCV replication and/or disease after transplantation. However, determining the best immunosuppressive strategies after kidney transplantation in the presence of HCV infection remains challenging. The use of induction therapy is not contraindicated, and a short-course induction may actually be beneficial in HCV-infected kidney transplant recipients. Corticosteroid withdrawal may be an acceptable option in HCV-infected patients with specific comorbidities such as diabetes mellitus or osteoporosis. The best calcineurin inhibitor to be used in HCV-infected patients remains to be determined, as there is a lack of large controlled trials addressing this particular issue. Overall, immunosuppressive regimens need to be individualized according to clinical parameters other than HCV, such as the patient's immunological risk and other comorbidities. In conclusion, there is a need for prospective controlled studies to define the optimal immunosuppressive regimen in HCV-infected kidney transplant recipients.
Mots-clé
Graft Survival, Hepatitis C/complications, Humans, Immunosuppression/adverse effects, Immunosuppression/methods, Immunosuppressive Agents/adverse effects, Immunosuppressive Agents/therapeutic use, Kidney Failure, Chronic/complications, Kidney Failure, Chronic/surgery, Kidney Transplantation/immunology
Pubmed
Web of science
Création de la notice
17/02/2012 17:00
Dernière modification de la notice
20/08/2019 15:21
Données d'usage